Clover Health Investments (CLOV) CEO Reynoso Sells $86K of Stock

Clover Health Investments, Corp. (CLOV) Medicare Advantage CEO Jamie L. Reynoso sold 18,273 shares of the company on October 15, 2026. The transaction was revealed in a Form 4 filing with the SEC. This follows earlier sales by Reynoso and other company leaders earlier in the year.

CLOV Clover Health Investments, Corp.

$4.44 ▲ +84.23% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Jamie L. Reynoso's Clover Health Trade

Reynoso executed the sale at $4.68 per share, bringing the total value of the transaction to $85,517.64. The trade was pre-arranged under a Rule 10b5-1 trading plan. Following the sale, Reynoso directly holds 2,774,417 shares in the healthcare company. This reduced her stake by about 0.65%.

Other Institutional Activity in Clover Health

Other large funds adjusted their positions earlier in the year. Nuveen, LLC grew its holdings by 5,356,158 shares, ending with 6,291,699 shares worth about $27,935,143. PNC Financial Services Group, Inc. reduced its stake by 200,251 shares, ending with 3,563,874 shares valued at roughly $15,823,600.

Clover Health Investments, Corp. Stock Down 7.3%

CLOV shares recently traded around $4.44 as of October 19, 2026, which is down about 5.1% from the $4.68 close on October 15, 2026. The stock is sitting below its 50-day moving average of $4.46 and above its 200-day moving average of $3.42. The recent price sits about 20.6% below its 52-week high of $5.59 and roughly 181.0% above its 52-week low of $1.58.

Recent Earnings

Clover Health generated $2,475,912,960 in trailing-twelve-month revenue with earnings of -$0.05 per share. The company reported a net profit margin of -0.7% and a return on equity of -5.1%. The next earnings report is scheduled for November 4, 2026.

Dividend

The company has a dividend yield of 0.0%.

Insider Buying and Selling at Clover Health Investments, Corp.

Insiders have executed several planned sales over recent months. Reynoso previously sold 6,350 shares on June 15, 2026, at $4.61 per share. Chief Legal Officer Karen Soares sold 4,681 shares on the same day at $4.61 per share. VP of Finance and Controller Oldakowski Joseph Frank sold 12,102 shares on June 16, 2026, at $4.86 per share. Reynoso also sold 2,360 shares on June 17, 2026, at $4.78 per share.

Analysts Set New Price Targets

Canaccord Genuity maintained a Buy rating on July 21, 2026, raising its price target to $5.50 from $4.20. UBS maintained a Neutral rating on August 6, 2026, lifting its target to $5.00 from $4.75. The stock carries a mean price target of $5.38 across four analyst opinions.

About Clover Health

Clover Health Investments, Corp. offers Medicare Advantage plans to individuals across the United States. The Wilmington, Delaware-based company provides preferred provider organization and health maintenance organization options. It also develops the Clover Assistant software platform to help physicians manage chronic illnesses.

Bottom Line

Investors will look toward the company's upcoming earnings release on November 4, 2026, for further financial updates. Insider trading forms provide visibility into executive stock management, though planned sales often reflect personal financial planning rather than a shift in business outlook.